SYS-CON MEDIA Authors: Adine Deford, Cynthia Dunlop, Harry Trott, Xenia von Wedel, Peter Silva

News Feed Item

Beauty School is In Session -- Create a No-Makeup, Makeup Look

Allergan, the makers of ACZONE®(dapsone) Gel 5% team up with celebrity makeup artist Julianne Kaye on new video tutorial

IRVINE, Calif., Aug. 20, 2014 /PRNewswire/ -- Renowned beauty expert and makeup artist to the stars Julianne Kaye is partnering with Allergan, the makers of ACZONE® (dapsone) Gel 5%, the No. 1 prescribed retinoid-free acne brand in the U.S., to offer expert skincare and makeup tips in an exclusive video posted today on www.aczone.com. 1 ACZONE® Gel is a prescription medicine used on your skin (topical) to treat acne in people 12 years and older.

"This time of year, my clients— particularly those with acne—are often concerned about being poolside or at the beach because it's not the best environment for heavy makeup," said Kaye. "The good news is you can still look fresh and pretty without loading on the concealer and foundation. That's why I am excited to partner with Allergan, the makers of ACZONE® Gel, to share tips and tricks for achieving one of my favorite looks. Makeup, of course, can only get you so far, so it's important to see a dermatologist to address any chronic skin conditions like acne."2

Acne is the most common skin condition in the United States, affecting 50 million Americans.3 Nearly 85% of people have acne at some point in their lives.3 In many cases, adults—particularly women—in their 20s, 30s, 40s, and even 50s can continue to have acne.3 However, people living with this chronic condition don't have to simply cope with their condition.2 Rather than self-treating or managing it alone, acne-sufferers can work with their dermatologist to identify treatments that are right for their skin and routine.

"The summer heat is not kind to acne-prone skin or the layers of makeup that we use to cover the blemishes and imperfections," said Doris Day, MD, MA, Clinical Associate Professor of Dermatology at New York University Langone Medical Center. "One medication I prescribe for acne lesions that can be worn under makeup is ACZONE® Gel. ACZONE® Gel does not make acne worse before it gets better. ACZONE® Gel is not known to cause sun sensitivity.4 And remember, sunscreen is a must-have regardless of your skin type."

To watch the video and for more skincare tips, please visit http://www.aczone.com/beauty-tips.

FDA-APPROVED USE
ACZONE® Gel is a prescription medicine used on your skin (topical) to treat acne in people 12 years and older.

IMPORTANT SAFETY INFORMATION
Do not use ACZONE® Gel if you are allergic to any of the ingredients in ACZONE® Gel or if you are younger than 12 years of age.

Tell your doctor about all of your medical conditions, including if you have glucose-6-phosphate dehydrogenase deficiency (G6PD) which may put you at a greater risk for developing a low red blood cell count. If you experience signs and symptoms such as back pain, breathlessness, tiredness/weakness with daily activities, dark-brown urine, high fever, and yellow or pale skin, stop use and call your doctor immediately.

The most common side effects of ACZONE® Gel are dryness, redness, oiliness, and peeling of the skin being treated.

Talk to your doctor about any medications you're using including topical benzoyl peroxide (BPO). Use of BPO with ACZONE® Gel may cause your skin to temporarily turn yellow or orange at the site of application.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information or visit www.aczone.com 

About Allergan

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 11,700 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: www.allergan.com.

Forward-Looking Statements

This press release contains "forward‐looking statements," including but not limited to, the statements by Ms. Kaye and Dr. Day as well as other statements regarding the safety and efficacy of ACZONE®. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and pharmaceutical market conditions; challenges related to achieving regulatory approval from the FDA on a timely and cost‐efficient manner; technological advances and patents attained by competitors; inconsistency of treatment results among patients; potential difficulties in manufacturing; challenges related to new product marketing, such as the unpredictability or market acceptance for new products and/or the acceptance of new indications for such products; and governmental laws and regulations affecting domestic and foreign operations. Allergan expressly disclaims any intent or obligation to update these forward‐looking statements except as required by law. Additional information concerning these and other risks can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's most recent Annual Report on Form 10‐K and any subsequent Quarterly Reports on Form 10‐Q. Copies of Allergan's press releases and additional information about Allergan are available at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 1‐714‐246‐4636.

Allergan Contacts

Heather Katt (714)697-2981; (714)246-6224 (media)
Jessica Chao (714)586-7707; (714)246-3151 (media)

© 2014 Allergan, Inc.
® marks owned by Allergan, Inc.

APC62OJ14  

1 IMS Health, Inc. Monthly IMS National Prescription Audit Data. April 2008March 2014
2 Gollnick H et al. Can We Define Acne as a Chronic Disease? Am J Clin Dermatol. 2008:9(5): 279-284.
3 American Academy of Dermatology. "Stats and Facts: Acne." Available online at http://www.aad.org/mediaresources/stats-and-facts/conditions/acne. Last accessed on October 17, 2013.
4 DraelosZD, Carter E, Maloney JM, et al; For United States/Canada DapsoneGel Study Group. Two randomized studies demonstrate the efficacy and safety of dapsonegel, 5% for the treatment of acne vulgaris. J Am AcadDermatol. 2007;56(3):439.e1-439.e10.

SOURCE Allergan

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
"We help companies that are using a lot of Software as a Service. We help companies manage and gain visibility into what people are using inside the company and decide to secure them or use standards to lock down or to embrace the adoption of SaaS inside the company," explained Scott Kriz, Co-founder and CEO of Bitium, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
15th Cloud Expo, which took place Nov. 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, expanded the conference content of @ThingsExpo, Big Data Expo, and DevOps Summit to include two developer events. IBM held a Bluemix Developer Playground on November 5 and ElasticBox held a Hackathon on November 6. Both events took place on the expo floor. The Bluemix Developer Playground, for developers of all levels, highlighted the ease of use of Bluemix, its services and functionalit...
The 4th International DevOps Summit, co-located with16th International Cloud Expo – being held June 9-11, 2015, at the Javits Center in New York City, NY – announces that its Call for Papers is now open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's large...
Some developers believe that monitoring is a function of the operations team. Some operations teams firmly believe that monitoring the systems they maintain is sufficient to run the business successfully. Most of them are wrong. The complexity of today's applications have gone far and beyond the capabilities of "traditional" system-level monitoring tools and approaches and requires much broader knowledge of business and applications as a whole. The goal of DevOps is to connect all aspects of app...
SAP is delivering break-through innovation combined with fantastic user experience powered by the market-leading in-memory technology, SAP HANA. In his General Session at 15th Cloud Expo, Thorsten Leiduck, VP ISVs & Digital Commerce, SAP, discussed how SAP and partners provide cloud and hybrid cloud solutions as well as real-time Big Data offerings that help companies of all sizes and industries run better. SAP launched an application challenge to award the most innovative SAP HANA and SAP HANA...
When an enterprise builds a hybrid IaaS cloud connecting its data center to one or more public clouds, security is often a major topic along with the other challenges involved. Security is closely intertwined with the networking choices made for the hybrid cloud. Traditional networking approaches for building a hybrid cloud try to kludge together the enterprise infrastructure with the public cloud. Consequently this approach requires risky, deep "surgery" including changes to firewalls, subnets...
Want to enable self-service provisioning of application environments in minutes that mirror production? Can you automatically provide rich data with code-level detail back to the developers when issues occur in production? In his session at DevOps Summit, David Tesar, Microsoft Technical Evangelist on Microsoft Azure and DevOps, will discuss how to accomplish this and more utilizing technologies such as Microsoft Azure, Visual Studio online, and Application Insights in this demo-heavy session.
DevOps is all about agility. However, you don't want to be on a high-speed bus to nowhere. The right DevOps approach controls velocity with a tight feedback loop that not only consists of operational data but also incorporates business context. With a business context in the decision making, the right business priorities are incorporated, which results in a higher value creation. In his session at DevOps Summit, Todd Rader, Solutions Architect at AppDynamics, discussed key monitoring techniques...
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water,...
The security devil is always in the details of the attack: the ones you've endured, the ones you prepare yourself to fend off, and the ones that, you fear, will catch you completely unaware and defenseless. The Internet of Things (IoT) is nothing if not an endless proliferation of details. It's the vision of a world in which continuous Internet connectivity and addressability is embedded into a growing range of human artifacts, into the natural world, and even into our smartphones, appliances, a...
How do APIs and IoT relate? The answer is not as simple as merely adding an API on top of a dumb device, but rather about understanding the architectural patterns for implementing an IoT fabric. There are typically two or three trends: Exposing the device to a management framework Exposing that management framework to a business centric logic Exposing that business layer and data to end users. This last trend is the IoT stack, which involves a new shift in the separation of what stuff happe...
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, discussed single-value, geo-spatial, and log time series dat...
An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, discussed how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will need to convince a skeptical public to participate. Get ready to show them the money!